ArticleScientific reports2025
Persistent versus resolved donor-specific antibodies predict 10-year antibody-mediated rejection and kidney transplant outcomes in Thailand.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Rejection-Focused Precision Medicine in Kidney Transplantation: Biology, Biomarkers, and Artificial Intelligence.Life (Basel, Switzerland) · 2026Review
- Renal Allograft Pathology Classifications: Contemporary Updates and Diagnostic Utility.Cureus · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Preformed donor-specific HLA antibodies (DSA) are a major risk factor for antibody-mediated rejection (ABMR) and graft loss after kidney transplantation. While pre-transplant desensitization can reduce DSA levels, the impact of persistent vs. resolved DSA on long-term outcomes remains unclear. This study investigated the association between post-transplant DSA status and clinical outcomes in kidney transplant recipients. This retrospective cohort study investigated the impact of post-transplant DSA persistence on clinical outcomes in kidney transplant recipients at King Chulalongkorn Memorial Hospital between 2009 and 2019. Patients with pre-transplant DSA positivity (detected by Luminex but negative by CDC-AHG) were categorized into 'resolved' (DSA < 500 MFI) and 'persistent' (DSA > 500 MFI) groups based on post-transplant Luminex results. Outcomes evaluated included biopsy-proven acute rejection (ABMR and TCMR), graft loss, mortality, and post-transplant complications. A total of 50 KTr were enrolled in the study. The median (interquartile range, IQR) DSA level was 1,556 (3,491) MFI for class I and 0 (888) MFI for class II. 57% of patients underwent pre-transplant desensitization. The median follow-up time after transplantation was 5.5 (IQR 3.3) years. The group with persistent DSA (n = 16) exhibited a significant higher rate of ABMR compared to the group with resolved DSA (n = 34) (p = 0.047, log-rank test). Factors associated with persistent DSA included recipient age over 50 and lower tacrolimus levels at six months (less than 7.25 ng/mL). Monitoring DSA levels is crucial in kidney transplant recipients, as persistent DSA is strongly associated with an increased risk of ABMR. Maintaining higher tacrolimus levels at 6 months tends to resolve DSA post-transplant. For patients with persistent DSA, surveillance biopsies should be considered to facilitate early detection and treatment of rejection, thus preserving kidney allograft function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.